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Summary 
Endothelial cells (EC) are a site of human cytomegalovirus (HCMV) productive replication, 
haematogeneous dissemination and persistence and are assumed to play a critical role in the  
development of HCMV associated vascular diseases. Although early reports have shown the presence of 
HCMV antigens and DNA in lymphoid tissues, the ability of HCMV to infect lymphatic endothelial 
cells (LECs) has remained unaddressed due to the lack of a suitable in vitro system. Here, we provide 
evidence that a clinical isolate of HCMV (retaining its natural endotheliotropism) productively infects 
purified lymph node-derived LECs and dysregulates the expression of several LEC genes involved in 
the inflammatory response to viral infection. Qualitative and quantitative analysis of virus-free 
supernatants from HCMV-infected LEC cultures revealed the virus-induced secretion of several 
cytokines, chemokines and growth factors, many of which are involved in the regulation of EC 
physiological properties. Functional assays, in fact, demonstrated that the secretome produced by 
HCMV-infected LECs stimulates angiogenesis in both LECs and blood ECs, and that neutralisation of 
either IL-6 or GM-CSF in the secretome causes the loss of its angiogenic properties. The involvement of 
IL-6 and GM-CSF in the HCMV mediated angiogenesis is further supported by the finding that the 
recombinant cytokines reproduce the angiogenic effects of HCMV secretome. These findings suggest 
that HCMV induces hemangiogenesis and lymphangiogenesis through an indirect mechanism that relies 
on the stimulation of IL-6 and GM-CSF secretion from infected cells. 
 
 
Introduction 
Epidemiological and animal studies have associated Human Cytomegalovirus (HCMV) infection 
with the acceleration of vascular disorders such as coronary artery disease, transplant vascular  
sclerosis (TVS), arterial stenosis and atherosclerosis; all conditions that are characterised by an 
inflammatory response with endothelial cell activation, inflammatory cell infiltration and smooth 
muscle cell proliferation (Mocarski et al., 2006; Britt, 2008; Streblow et al., 2008). The ability of 
the virus to infect vascular endothelial cells (ECs) and to dysregulate their gene expression profiles,  
their physiological states of activation and differentiation and their interactions with other cell types 
is thought to be crucial in HCMV pathogenesis (Digel & Sinzger, 2006; Britt, 2008; Adler & 
Sinzger, 2009; Revello & Gerna, 2010). In fact, the reprogrammed gene expression of the HCMV 
infected EC is associated with the stimulation of genes involved in the generation of pro  
inflammatory responses, such as cytokines, chemokines, leukocyte adhesion molecules, 
extracellular matrix proteins and inflammatory mediators (Caposio et al., 2007a; Dumortier et al., 
2008; Streblow et al., 2008). Hence, activation of the endothelium, dysregulation of EC 
inflammatory gene expression and subsequent virus-mediated immunopathogenesis, inflammatory 
cell recruitment and persistence in ECs are all thought to contribute to the pathogenesis of virus  
induced vascular damage (Britt, 2008; Soderberg-Nauclér, 2006, 2008; Streblow et al., 2008). The 
lymphatic vascular system is comprised of a network of blind-ended, thin walled lymphatic 
capillaries, collecting vessels that regulate tissue homeostasis and direct antigens, cytokines and 
antigen-loaded presenting cells from sites of inflammation to draining lymph nodes to initiate 
immune responses (Ji, 2005). Studies performed with relatively pure populations of lymphatic ECs 
(LECs) and blood EC (BECs) have revealed that, although LECs have many properties in common  
with BECs, they express distinct sets of vascular markers and differentially respond to growth 
factors and the extracellular matrix (Ji, 2005). Moreover, comparative analyses of gene-expression 
profiles have revealed that a number of genes involved in protein sorting and trafficking are 
selectively expressed by LECs (Podgrabinska et al., 2002). Lymphangiogenesis, the growth of 
lymphatic vessels from pre-existing vasculature, is modulated, like BEC angiogenesis, by multi 
factors and occurs as part of various pathological processes, such as wound healing, diabetes, 
tumour growth, lymphedema and microbial infections (Ji, 2005). For example, inflammatory 
lymphangiogenesis during bacterial infection is thought to depend on the recruitment of activated 
macrophages to sites of pathogen-induced inflammation and the subsequent production of the 
prolymphangiogenic vascular endothelial growth factor (VEGF) C and D that, in turn, bind to the 
LEC expressed receptor VEGFR3, inducing cell proliferation a 79 nd lymphatic vessel branching 
(Cueni & Detmar, 2008). However, the mechanisms leading to the lymphangiogenic response 
during virus-induced inflammation have not yet been defined. To this regard, although early reports 
have shown the presence of HCMV antigens and DNA in lymphoid tissues (Boriskin et al., 1999; 
Chen & Hudnall, 2006), the importance LECs as a target of HCMV infection has remained  
unaddressed due to the lack of suitable in vitro experimental systems. The aim of the present study 
was thus to investigate the ability of HCMV to infect LECs and affect their physiological properties. 
 
 
Results 
HCMV infection of LECs. LECs were successfully purified and expanded in vitro from fresh 
lymph nodes as previously described (Garrafa et al. 2005, 2006). Purified LECs (>95%) showed the 
typical morphology of ECs and expressed both the endothelial marker CD31 and the specific 
lymphatic markers podoplanin and Prox-1, thus providing confidence about the lymphatic lineage 
of these cells (data not shown). To investigate the frequency of HCMV infection, purified LECs and 
HUVECs (as control) were infected with the EC-strain VR1814 at an infection multiplicity of 1 and 
examined by immunofluorescence at various times p.i. for the presence of IEA (IE1+IE2), UL44 
and UL99 as a control for HCMV IE, E and L proteins. As Fig. 1A indicates, no significant 
differences in the frequency of HCMV antigen detection were observed between LECs and 
HUVECs and the kinetics of viral antigen expression was similar in both EC types, since by 4 d.p.i., 
60% of HUVECs and 57% of LECs dislayed the presence of UL99. Thus, the frequency of infected 
cells and the kinetics of viral gene expression were similar in both the EC types. To circumstantiate 
the ability of LECs to sustain viral growth, one-step growth curves were generated from cells 
infected with the VR1814 and, as a control, from HUVEC and HACEC cultures. As can be seen in 
Fig. 1B, VR1814 successfully replicated in all the EC types examined. However, from 6 d.p.i. the 
amount of cell-free virus detected in supernatants  from HCMV infected-LECs was lower than that 
measured in HUVEC and HACEC cultures. Thus, to determine the ability of infected LECs to 
spread virus, infectious center assays for virus-producing cells were performed with VR1814 
infected LECs and HUVECs at 6-12 d.p.i., that is the time frame in whichinfectious intracellular 
virus accumulates in LECs. As shown in Fig.1C, the percentage of infected LECs actively shedding 
virus was significantly lower than that determined for HUVECs, thus suggesting that infectious 
intracellular HCMV produced in LECs is slowly released from infected cells. Accordingly, the 
development of a fully cytopathic effect in LECs infected up to 22 d.p.i. was slower than that 
observed in HUVECs (data not shown). Altogether, these results demonstrate that LECs support 
productive HCMV replication, albeit with kinetics of infectious viral particle release which seem to 
be different from those observed in other ECs, like HUVECs.  
HCMV stimulates the expression of pro-inflammatory genes in infected LECs. We next 
investigated the effects of HCMV infection on the expression of proinflammatory genes in LECs.  
Quantitative real time RT-PCR demonstrated (Fig. 2) that infection of LECs with VR1814 for 96 h 
increased ICAM-1, VCAM-1 and E-selectin mRNA expression. Similarly, expression of the pro121 
inflammatory cytokine IL-6 and inflammatory chemokines CCL2 (MCP-1), CCL5 (RANTES), 
CCL20 (MIP-3 ), CXCL8 (IL-8), CXCL10 (IP-10) and CXCL11 (I-TAC) was induced by VR1814 
infection. In contrast, the levels of all these mRNAs were unaffected in cells infected with UV124  
inactivated HCMV, demonstrating that newly synthesised viral proteins are required for the virus 
mediated expression. It is worth noting that HCMV infection did not lead to the induction of 
VEGF-A mRNA expression (Fig. 2A) and that no detectable VEGF-A was measured in 
supernatants derived from HCMV infected LECs (data not shown). A more detailed time course 
analysis of ICAM-1, IL-8, IP-10 and RANTES mRNA expression in infected LECs or HUVECs 
then revealed different expression kinetics for the two EC types (Fig. 2B). In fact, ICAM-1 and IL-8 
mRNA levels were significantly increased by HCMV at 48 and 96 h.p.i. in HUVECs and to a lesser 
extent  in LECs. In contrast, IP- 10 and I-TAC gene expression was induced to a higher extent in 
infected LECs compared to HUVECs at all of the time points analysed (Fig. 2B). Taken together, 
these results indicate that infection of LECs by HCMV increases the expression of proinflammatory 
and proangiogenic molecules. 
HCMV-induced secretome from infected LECs stimulates EC angiogenesis and migration.  
Since some of the HCMV-dysregulated genes in LECs are involved in the regulation of 
angiogenesis (Carmeliet, 2003), we investigated whether the conditioned medium (secretome) from  
HCMV-infected LECs might affect the physiological properties of ECs that relate to angiogenesis  
such as cell migration and differentiation. In order to do so, in vitro hemangiogenesis and  
lymphangiogenesis assays were performed to evaluate the ability of HUVECs and LECs to form  
capillary-like tubules on basal membrane extracts (Cultrex BME) in the presence of factors that  
promote angiogenesis. As illustrated in Fig. 3A, HUVECs cultured in complete EGM 
spontaneously formed a robust meshwork of anastomosing tubules with multi-nodal branch points 
and enclosed lumens. When they were incubated in the presence of virus-free supernatant from 
LECs infected with VR1814 at an infection multiplicity of 3 for 96 h, a condition that produced  
more than 95% infection rate as assessed by immunofluorescence analysis (Fig. S1), the formation  
of an extensive network of interconnecting capillary-like structures was observed (Fig. 3A). In 
contrast, HUVECs incubated in the presence of control medium (EBM), or in presence of  
secretomes from mock-infected LECs or from UV-inactivated VR1814-infected LECs did not form 
a consistent network of capillary-like structures, with most cells generating incomplete tubules or 
aggregating in clumps (Fig. 3A). These microscopic observations were confirmed by the  
quantification of the extent of hemangiogenesis through the evaluation of the number of lumens  
delimited by intact capillary-like tubule structures (Fig. 3A, lower panel). Similarly, when LECs 
were cultured on BME in the presence of EGM, a wide array of capillary like structures was 
observed, although they were less robust than those formed by HUVECs (Fig.  3B). The incubation 
of LECs with the VR1814 secretome from infected LECs significantly induced the formation of an  
intact capillary network that was not observed in LECs cultures incubated with  secretomes either 
from mock- or UV-inactivated VR1814-infected LECs (Fig. 5A). Again, quantification of 
lymphangiogenesis by counting LEC lumens confirmed the microscopic observations (Fig. 3B, 
lower panel). Finally, we evaluated the effects of the VR1814 secretome from infected LECs on in 
vitro wound healing following mechanical injury in order to assay the migration phase of 
angiogenesis. Confluent HUVEC monolayers were scratched with a 200- L micropipette tip and 
incubated in the presence of secretomes from mock-infected LECs or from VR1814-infected LECs. 
As shown in Fig. 4, HUVECs cultured in the presence of the mock secretome were unable to 
entirely repopulate the wound and reached only 12±9% of sealing 24 h after the scratch; whereas 
the addition of the VR1814 secretome from infected LECs resulted in the considerable repair of the 
scrape wound with about 76±16% of sealing over the same period of observation (Fig. 4B), thus 
suggesting that the VR1814 secretome contains factors that promote EC migration into a 
mechanical wound. Altogether these results demonstrate that the secretome derived from VR1814-
infected LECs contains factors that promote the migration and differentiation phases of 
angiogenesis of two different types of EC, and that active HCMV replication is required for the 
production of the angiogenic secretome since supernatants of LECs infected with UV-inactivated 
VR1814 failed to sustain the angiogenic response. 
Detection of factors in the secretome of VR1814-infected LECs. To investigate the qualitative 
and quantitative composition of the secretome derived from VR1814-infected LECs, virus-free 
supernatants were analysed for the occurrence of 174 cytokines and growth factors using the 
RayBiotech human cytokine antibody array series G2000. Comparative analysis of secreted factors  
between mock- and HCMV-infected secretomes revealed the presence of 38 significantly induced 
factors (Table 1). The VR1814-mediated secretion of most of induced factors was not observed in 
the secretome derived from LECs infected with UV-inactivated virus, thus further supporting the 
view that active HCMV replication is required to produce a secretome with angiogenic properties.  
The 20 most abundant factors measured in the LEC secretome included the cytokines IL-1 , IL-3, 
IL-5, IL-6, IL-13, IL-15, GM-CSF and TNF- , and the chemokines MIP- , GRO , ENA-78, I-309, 
I-TAC, MCP-3 and MIG (Table 2). Furthermore, HCMV infection of LECs also induced the release 
of receptors such as ICAM-1 and TNF-R1, growth factors like TGF- 1 and b-FGF and the 
extracellular matrix modifier MMP-1. Taken as a whole, these results demonstrate the complexity 
of the HCMV-induced LEC-derived secretome and the presence of several factors involved in the 
promotion of angiogenesis. 
HCMV-induced IL-6 and GM-CSF mediate lymphangiogenesis and angiogenesis. To gain 
deeper insight into the mechanism of HCMV-induced EC angiogenesis, we next addressed the role 
of IL-6 and GM-CSF. These two cytokines were examined because: i) their expression was strongly 
induced by HCMV (Table 1); ii) they are among the most abundant factors detected in the 
secretome generated by infected LECs (Table 2); iii) they have been reported to positively affect  
BEC angiogenesis (Yao et al., 2006; Krubasik et al., 2008). To this end, we used anti-IL-6 and anti- 
GM-CSF mAbs at concentrations able to neutralise more than 99% of the biological activity of the  
respective cytokines. The presence of neutralising antibodies against either IL-6 or GM-CSF almost 
completely abrogated the hemangiogenic (Fig. 5A) and lymphangiogenic (Fig. 5B) effects of the 
LEC-derived HCMV secretome. A mouse IgG1 anti-human CD3 mAb was used as an unrelated 
control and did not influence the HCMV-mediated angiogenesis (data not shown). Next, to support 
further the role of IL-6 and GM-CSF in the HCMV-induced angiogenesis, the two cytokines, in the 
form of recombinant proteins, were added to the supernatant from mock-infected LECs that was 
subsequently used in an in vitro lymphagiogenesis assay. As shown in Fig. 6, the presence of the 
supernatant from the mock-infected LECs did not significantly stimulate, as expected, tubular 
morphogenesis in cultured LECs (panel B). In contrast, the addition of recombinant GM-CSF 
(panel E) or IL-6 (panel F) to the mock-infected LEC secretome induced the differentiation of LECs 
with the formation of a consistent network of  interconnecting capillary-like structures, thus 
indicating that the sole addition of either IL-6 or GM-CSF restored the pro angiogenic properties of 
the HCMV-induced secretome. Once again, these effects were specifically blocked by the use of 
anti-cytokine neutralising antibodies (data not shown). Moreover, the addition of recombinant MIP-
3- , the second most abundant factor in the VR1814 secretome (Table 2), did not significantly 
induce the formation of a network of capillary-like structures (panel D), thus supporting the 
specificity of IL-6- and GM-CSF-dependent pro-angiogenic activity. Taken together, these results 
clearly identify IL-6 and GM-CSF as the main HCMV-induced soluble effectors that mediate the 
hemangiogenic and lymphangiogenic properties of the secretome derived from virus infected-LECs. 
 
 
Discussion 
This study was undertaken to investigate the in vitro susceptibility of purified lymphatic endothelial 
cells (LECs) to HCMV infection and to analyse the effects of viral infection on the LECs 
physiological properties. The importance of lymphatic endothelia as a putative in vivo target of 
HCMV infection has been suggested by reports showing the presence of viral antigens and DNA in  
lymphoid tissues (Boriskin et al., 1999; Chen and Hudnall, 2006), as well as by cases of intestinal  
lymphangiectasia and protein losing enteropathy in immunocompetent children and adults that have 
been associated with chronic inflammation caused by HCMV infection and the presence of HCMV 
DNA in the mucosa of the terminal ileum (Nakase et al., 1998; Hoshina et al., 2009; Kapetanos et  
al., 2010). Although the pathogenesis of lymphangiectasia in HCMV infection has not been 
clarified, it has been hypothesised that the local virus mediated-inflammatory response and the 
endothelial cell injury may contribute to the development of the damage of the network of  
lymphatic vessels within the mucosa of the small intestine (Nakase et al., 1998). Thus, despite the 
fact that lymphatic tissues may represent a relevant reservoir for HCMV replication and persistency 
in the host, prior this study no information was available on the  permissiveness of the lymphatic 
endothelium to HCMV infection, mostly because the lack of suitable in vitro systems. Taking 
advantage of the procedures we recently developed to isolate highly purified LECs (Garrafa et al.,  
2005, 2006), in the present study we have demonstrated that LECs are susceptible to HCMV 
infection and fully support the productive replicative cycle of an endotheliotropic clinical isolate of 
the virus. Moreover, HCMV infection of LECs resulted, as already established for infected BECs, 
in the stimulation of the expression of cellular genes encoding inflammatory effectors such as 
chemokines, cytokines and adhesion molecules (Fig. 2). Since some of these effector molecules 
have been demonstrated to contribute to EC migration and differentiation (Carmeliet, 2003), we 
investigated whether the whole set of soluble proteins released into the supernatant from infected 
LECs (the so-called HCMV secretome; Dumortier et al., 2008; Streblow et al., 2008) influences cell 
migration and capillary-like formation; i.e. these two phenomena were used as in vitro assays 
indicative of two different angiogenic functions (migration and morphogenesis). The results of 
these in vitro assays clearly showed that HCMV infection of LECs induces a secretome that 
promotes an angiogenic response in both a homologous and heterologous EC types, thus suggestive 
of both autocrine and paracrine effects. Furthermore, the LEC-derived HCMV secretome was found 
to contain factors that effectively induced cell migration in a mechanical wound. To this regard, it 
was very recently reported that the secretome derived from HUVECs infected with the VR1814 
strain of HCMV stimulates angiogenesis in the same EC type (Botto et al., 2010). In this study, a 
detailed analysis of the qualitative and quantitative composition of the HUVEC-derived secretome 
was performed and 29 soluble factors were found to be significantly induced by HCMV infection. 
Comparison of the HUVEC-derived (Botto et al., 2010) and LEC-derived VR1814 secretomes 
(Tables 1 and 2) indicates the occurrence of quantitative rather than qualitative differences since the 
majority of the most abundant secreted factors were found in both secretomes. For example, in the 
HUVEC-derived secretome, the chemoattractants RANTES, MIP-3α and MCP-3 and the cytokine 
IL-6 were identified as the most abundant factors. Whereas, in the LEC-derived secretome, we 
observed  that the content of IL-6, MIP-3α, GRO-α and GM-CSF were the highest among the 20 
most abundant factors (Table 2), with levels of IL-6 and GM-CSF that were respectively similar and 
more than two-fold those measured in the HUVEC-derived secretome. The content of the latter two 
cytokines in the supernatant of infected LECs was also the most increased by HCMV (36- and 14-
fold, respectively). Thus, it is likely that the differences between the two secretomes are due to the 
different cell types used (HUVEC vs. LEC) for the production of the HCMV-induced supernatants. 
Since it has been reported that IL-6 and GM-CSF promote hemangiogenesis (Yao et al., 2006; 
Krubasik et al., 2008), we addressed their role in the angiogenic response triggered by the LEC  
derived HCMV secretome by blocking their induced cell signalling using neutralising antibodies. 
These experiments clearly demonstrated that the neutralisation of IL-6 or GM-CSF reduced the 
ability of the HCMV secretome to stimulate the angiogenesis of both blood and lymphatic ECs by  
about 90%. Moreover, we confirmed the role of both cytokines as promoting factors in the 
angiogenic response of LECs by analysing the effects of recombinant IL-6 or GM-CSF on the 
LECs’ ability to form tubular structures (Fig. 6). In agreement with our findings, Botto et al. (2010) 
have identified IL-6 in the secretome of VR1814-infected HUVECs as the main mediator of 
neovessel formation and survival. However, they did not observed a significant GM-CSF-dependent 
hemangiogenic effect in the same secretome (Botto et al., 2010).  
This different result could be explained by the lower concentration of GM-CSF in the HUVEC-
derived secretome than that measured in the VR1814-infected LEC secretome (Table 2) which 
supports hemangiogensis and lymphangiogensis in our in vitro models. The most important result 
from these experiments is indeed that IL-6 and GM-CSF are responsible for mediating the 
hemangiogenic and lymphangiogenic effects of the HCMV secretome and that these effects are 
consequent to the ability of HCMV to stimulate the expression and secretion of these cytokines in 
infected ECs (Almeida-Porada et al., 1994, 1997). Thus, HCMV can elicit through this indirect 
mechanism lymphatic neovessel formation which could affect graft rejection upon reactivation in 
transplant recipients. Furthermore, we have shown for the first time that recombinant 285 IL-6 and 
GM-CSF stimulate tubular morphogenesis of purified LECs. Of particular relevance to this, in an 
vivo murine model of primary congenital lymphoedema Karlsen and colleagues observed that an 
increase in the level of IL-6 content in interstitial fluids was associated to deranged 
lymphoangiogenesis (Karlsen et al., 2006). The results of the present study, as well as those of 
Dumortier et al., (2008) and Botto et al., (2010) indicate that the release of growth and 
differentiation factors in virus-induced secretomes promotes angiogenesis by an indirect mechanism 
mediated by HCMV. In contrast, Bentz & Yurochko (2008) reported that human microvascular ECs 
(HMECs) infected with HCMV TB40/E display an increase in proliferation, motility and capillary 
tube formation (Bentz & Yurochko, 2008). In an attempt to investigate whether VR1814 infection 
directly affects the angiogenic response of LECs, HCMV infected LECs were plated onto 
preformed BME plugs in order to assess their ability to form tube like structures. However, no gross 
differences in the ability to form capillary-like tubules were observed between mock-, UV-
inactivated VR1814- and VR1814-infected LECs, suggesting that, at least in our experimental 
model, a direct effect of viral infection did not significantly contribute to the angiogenic response to 
HCMV infection (data not shown). The finding that the angiogenic effect of the HCMV secretome 
depends on IL-6 and GM-CSF deserves a further consideration since it was shown that HCMV 
infection stimulates the expression of VEGF in human foreskin fibroblasts and smooth muscle cells 
(Reinhardt et al., 2005). 
Furthermore, it has been recently reported that corneal HSV-1 infection in immunologically normal 
mice induces lymphangiogenesis that was related to the up-regulation of VEGF-A expression in 
infected epithelial cells (Wuest & Carr, 2010). In our study, we observed that HCMV infection of  
LECs does not result in a significant simulation of VEGF-A mRNA expression (Fig. 2A); moreover, 
cytokine antibody array analysis did not reveal any stimulation of VEGF-A, VEGF-C and VEGF-D 
release into the secretome from VR1814-infected LECs compared to the mock310 infected cells 
(data not shown). Thus, the HCMV-mediated mechanism of lymphangiogenesis in our in vitro EC 
models, differs from the reported HSV-1-induced effect 311 since it does not depend on VEGF, 
thus indicating an autocrine effect that depends on IL-6 and GM-CSF secretion. 
In conclusion, this study is the first to demonstrate (i) the permissiveness of LECs to HCMV 
replication, ii) the induction of a LEC-derived HCMV secretome that stimulate both 
hemangiogenesis and lymphangiogenesis, and (iii) that the virus-induced secretion of IL-6 and GM-
CSF mediates the indirect angiogenic response of ECs. These findings contribute to the deepening 
of our knowledge of the complexities of the virus-associated pathogenetic effects that occur during 
the development of HCMV-associated vascular disease, and thus enable us to understand better the 
molecular mechanisms elicited by the virus that regulate EC responses to viral infections. 
 
 
Methods 
EC isolation and culture conditions. Human umbilical vein endothelial cells (HUVECs) and 
human adrenocortical endothelial cells (HACEC) were isolated, characterized and cultured as 
previously described (Ricotta et al., 2001). Experiments were carried out with cells at passages 2–5. 
Lymphatic endothelial cells (LECs) were isolated from human lymph node specimens that appeared 
normal on histological examination and obtained from patients undergoing therapeutic surgical 
procedures. Approval was obtained from the University of Brescia institutional review board. 
Informed consent was provided according to the Declaration of Helsinki. Tissue samples were 
immediately transferred to the laboratory and treated as previously described (Garrafa et al., 2006). 
Briefly, lymph nodes were finely minced and digested in a 0.25% (w/v) collagenase/dispase 
solution (Boehringer Mannheim). The resulting digestion product was cultured in flasks coated with 
type I collagen (Boehringer Mannheim) in the presence of Endothelial Growth Medium (EGM) 
(Clonetics). Once 80-90% confluence was achieved, ECs were isolated by magnetic separation 
using anti-human CD31 beads (Miltenyi Biotech). Total CD31+ ECs were further cultured, and 
LECs were purified from ECs by incubation for 20 min at 4 °C with a mouse anti-human 
podoplanin mAb (RELIATech). After incubation, podoplanin+ ECs were recovered by magnetic 
separation with anti-mouse antibodies-coated magnetic microbeads (337 Miltenyi Biotec). Purified 
LECs were cultured in collagen coated flasks with EGM plus VEGF-C as previously described 
(Garrafa et al., 2005, 2006). All of the experiments were performed between the 3rd and 5th in vitro 
passage. Quiescent ECs (arrested in G0/G1) were obtained by culturing subconfluent cultures in 
EBM containing 0.5% FBS and supplements, but lacking VEGF, hFGF, hEGF, and IGF-1. 
Virus and virological methods. HCMV VR1814 is a derivative of a clinical isolate and grows 
efficiently on HUVECs (Revello et al., 2001). It was propagated in HUVECs and titrated on human 
embryonic lung fibroblasts (HELFs) cells as previously described (Caposio et al., 2007b). 
UVinactivated VR1814 was prepared with a single pulse of 1.2 J/cm2 of UV light. The UV-
inactivated VR1814 did not replicate in HELFs or produce detectable levels of IE gene products. 
Infectious center assays were performed as previously described (Luo & Fortunato, 2007).  
Immunofluorescence analysis. Immunofluorescence analysis of viral antigens was performed as  
previously described (Caposio et al., 2004) using mouse mAbs against IEA (IE1 plus IE2) (clone 
E13, Biosoft), UL44 (clone CH16, Virusys) or UL99 (clone CH19, Virusys). The binding of  
primary antibody was detected with Texas Red-conjugated goat anti-mouse Ig (Molecular Probes)  
antibodies. The nuclei were counterstained with DAPI. Samples were observed under a Zeiss  
Axiovert 25 fluorescence microscope equipped with AxioVision 4.8 software. The infection rate  
was calculated as the ratio of antigen positive cells of total cells.  
RT-PCR analysis. Total RNA was extracted from mock-, UV-HCMV- and HCMV-infected LECs 
harvested at the indicated h p.i. using the Quiagen RNeasy mini kit (Qiagen). After reverse358  
transcription into cDNA, the relative amounts of transcripts were determined by real-time PCR. 
Amplification was carried out for the following transcripts: IL-6, CXCL8 (IL-8), CCL2 (MCP-1), 
CCL5 (RANTES), CXCL10 (IP-10), CCL20 (MIP-3a), CXCL11 (I-TAC), ICAM-1, VCAM-1, 
E361 selectin, VEGF-A and β-actin (Taqman gene expression assays, Applied Biosystem). Data 
obtained were analyzed with the 2-ΔΔCt method using the Relative Quantification Study software 
(Appied Biosystems). The Ct values for each gene were normalized  to the Ct values for -actin. 
Production of secretomes, angiogenesis and wound sealing assay. Cell and virus-free secretomes 
were isolated from mock-, VR1814- and UV-inactivated VR1814-infected (infection multiplicity of 
3) LECs at 96 h p.i.. Particles were removed from supernatants using Centricon YM-100 (Amicon 
inc., 22,000 rpm for 60 min at 4°C). For the angiogenesis assay, HUVECs or LECs were starved for 
24 h in EBM pus 0.5% FBS and then cultured for 24 h with the LEC-derived secretomes. Control 
cells were treated with EBM plus 0.5% FBS (negative control) or with EGM plus 2% FBS (positive 
control). Thereafter, cells were resuspended and plated (7 x 104/well) on preformed CultrexTM 
Basement Membrane Extract (BME; 10 mg/ml, Tevigen) plugs in 24-well plates. Wells were 
analysed for tube formation after 8 h by examination with a phase contrast inverted microscope 
equipped with a digital camera. To quantitatively compare induced angiogenesis and 
lymphangiogenesis, digital images were analysed for the number of polygonal spaces delimited by 
tubules and branch points (lumens). For experiments involving antibody neutralisation, HUVECs or 
LECs were starved for 24 h in EBM plus 0.5% FBS and then cultured for 24 h with the LEC-
derived VR1814 secretomes in the presence or absence of mouse mAbs anti-human IL-6 (10 μg/ml, 
Diaclone,) and/or anti-human GM-CSF (10 μg/ml, Calbiochem) neutralising antibodies, or a mouse 
mAb anti-human CD3 (10 g/ml, AbD Chemicon) as an unrelated control. For evaluation of the 
angiogenic properties of recombinant IL-6, GM-CSF and MIP-3- , LECs were serum starved for 
24 h in EBM plus 0.5% FBS, then treated for 24 h in the presence of the supernatant from mock-
infected LECs containing exogenously added recombinant hIL-6 (PeproTech), or hMIP-3-
(PeproTech), or hGM-CSF (PeproTech). Control cells were maintained in the secretome of mock-
infected LECs (negative control) or EGM plus 2% FBS (positive control). Cells were harvested and 
transferred onto BME-coated wells and lymphangiogenesis was assessed following the same 
procedure as described above. The wound sealing assays were performed as previously described 
( 389 Caruso et al., 2009). 
Human cytokine protein array. The RayBiotech Human cytokine antibody array series G2000 for 
the detection of 174 human cytokines (the list of factors is reported on www.raybiotech.com) was 
used to assay the secretomes produced from mock-infected, VR1814-UV inactivated-infected and 
VR1814-infected LECs at 96 h.p.i. After centrifugation to remove virus particles, triplicate 
biological replicates of secretomes were concentrated three-fold using Amicon Ultra-4 (Millipore) 
and then assayed according to the manufacturer’s procedures. Values were subtracted from local  
background and normalised with respect to the positive and negative controls. Mock-infected, 
VR1814-UV inactivated-infected and VR1814-infected values were compared and P ≤0.05 were 
considered as statistically significant.  
Statistical analysis. The results are expressed as the mean±SD for three independent experiments.  
Data were analysed for significance using one-way ANOVA with Bonferroni post-test correction 
for multiple comparisons. A P value ≤0.05 was considered significant. 
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Table 1. LEC-derived secretome factors induced by HCMV VR1814. 
Factors values (in arbitrary units) were derived by RayBiotech cytokine array analysis. Means±sd 
are shown for mock-, UV-inactivated HCMV- and HCMV-infected intensity values. BDNF, Brain-
derived neurotropic factor; bFGF, basic fibroblast growth factor; BLC, chemokine B lymphocyte 
chemoattractant; BMP, bone morphogenetic protein; EGF, epidermal growth factor; ENA, 
epithelial neutrophil-activating protein; GCP, granulocyte chemoattractant protein; GDNF, glial 
cell-derived neurotropic factor; GM-CSF, granulocyte–macrophage colony-stimulating factor; GRO, 
growth-related oncogene; IFN, interferon; MIG, monokine induced by gamma interferon; MMP, 
matrix metalloproteinase; s, soluble; SDF, stromal cell-derived factor; TGF, transforming growth 
factor; TNF, tumour necrosis factor.  
 
 
 
Table 2. Most abundant factors induced in the LEC-derived secretome by HCMV VR1814 
infection Factors values (in arbitrary units) were derived by RayBiotech cytokine array analysis. 
Means±sd are shown for HCMV-infected intensity values.  
 
 
  
 
Fig. 1. Endotheliotropic HCMV VR1814 strain replicates productively in LECs. (a) Expression 
of HCMV proteins in infected LECs and HUVECs. LECs or HUVECs were infected with VR1814 
at an m.o.i. of 1. At the indicated times p.i., cells were fixed, permeabilized and stained with anti -
IEA (IE1+IE2), anti-UL44 or anti-UL99 mAb. Immunofluorescence experiments were repeated 
three times and representative results are presented. Magnification, ×10. (b) Growth kinetics of 
VR1814 in LECs, HUVECs and HACECs. LEC, HUVEC or HACEC cultures were infected with 
VR1814 at an m.o.i. of 1. The extent of virus replication was measured at the indicated times p.i. by 
titrating the infectivity of supernatants and cell suspensions on human embryonic lung fibroblasts 
(HELFs) by an IE antigen immunostaining technique. Results are expressed as means±sd. (c) 
VR1814 infected LECs spread fewer infectious virus particles than HUVECs. LECs or HUVECs 
were infected with VR1814 at an m.o.i. of 1. The percentage of virus-shedding cells was 
determined at the indicated times p.i. by an infectious centre assay. Results are expressed as the 
percentage (means±sd) of focus-forming cells. *, P<0.05 versus HUVECs.  
 
  
 
Fig. 2. HCMV infection stimulates the expression of pro-inflammatory genes in LECs. (a) 
Stimulation of cytokine, chemokine and adhesion molecule mRNA expression in VR1814-infected 
LECs. LECs or HUVECs were infected with VR1814 or UV-inactivated VR1814 at an m.o.i. of 3 
or were mock infected. Total RNA was isolated at 96 h p.i. and reverse transcribed. Real-time RT-
PCR was then carried out with appropriate IL-6, MIP-3α, RANTES, MCP-1, E-selectin, VCAM, 
VEGF-A and β-actin primers. RNA levels were normalized according to expression of the β-actin 
gene. The values were then normalized to the value observed in mock-infected cells, which was set 
at a value of 1. (b) Kinetics of ICAM-1, IL-8, IP-10 and I-TAC mRNA expression in VR1814-
infected LECs or HUVECs. Total RNA was isolated at the indicated times p.i. from LECs or 
HUVECs infected as described above and reverse transcribed. Real-time RT-PCR was then carried 
out with appropriate ICAM-1, IL-8, IP-10, I-TAC and β-actin primers. The value at each time point 
was normalized to the value observed with cells infected for 12 h, which was set at a value of 1. 
Data are shown as means±sd. *, P<0.05; **, P<0.001; both versus calibrator sample.  
 
 
 
  
 
Fig. 3. The secretome derived from VR1814-infected LECs stimulates haemangiogenesis and 
lymphangiogenesis. HUVECs (a) or LECs (b) were serum starved for 24 h in EBM plus 0.5% FBS 
and then incubated for 24 h with LEC-derived secretomes, EBM plus 0.5% FBS (negative control) 
or EGM plus 2% FBS (positive control). Cells were then resuspended and plated on preformed 
Cultrex plugs in 24-well plates. The wells were analysed for tube formation by microscopic 
examination after 8 h. Representative examples of each culture condition are shown. Magnification, 
×10. To evaluate quantitatively the HCMV-induced haemangiogenesis (a) or lymphangiogenesis (b), 
digital images were analysed for the number of enclosed polygonal spaces delimited by complete 
tubules (lumens). The data shown represent means±sd. *, P<0.05; **, P<0.001; both versus mock-
derived secretome.  
 
 
 
 
 
  
 
Fig. 4. The secretome of VR1814-infected LECs stimulates EC migration. EC migration was 
evaluated using a wound healing assay. Confluent HUVEC monolayers were starved for 24 h and 
then scratched using a 200 μl micropipette tip (vertical lines). After washing, the medium was 
replaced with EBM plus 0.5   % FBS (negative control), EGM plus 2% FBS (positive control) or 
secretomes obtained from mock- or VR1814-infected LECs. HUVEC migration was then recorded 
by light microscopy over a 24 h time course following wound scratching. (a) Representative images 
of wound sealing at 0 and 24 h after the wound scratch. Magnification, ×10. (b) Quantification of 
cell migration into the wound at 24 h. Results are expressed as means±sd. **, P<0.001 versus 
mock-derived secretome.  
 
 
Fig. 5. Neutralization of IL-6 or GM-CSF in the supernatant from VR1814-infected LECs 
prevents the haemangiogenic and lymphangiogenic activity of the HCMV-induced secretome. 
HUVECs (a) or LECs (b) were serum starved for 24 h in EBM plus 0.5% FBS and then incubated 
for 24 h with EBM plus 0.5   % FBS (negative control), EGM plus 2% FBS (positive control) or the 
VR1814-infected LEC secretome. Where indicated, neutralizing mAb against IL-6 or GM-CSF was 
added at a concentration of 10 μg ml−1. After 24 h, cells were resuspended and plated on preformed 
Cultrex plugs in 24-well plates. Wells were then analysed for tube formation by examination with a 
phase-contrast inverted microscope at 8 h. Representative examples of each culture condition are 
shown. Magnification, ×10. HUVEC angiogenesis (a) or LEC lymphangiogenesis (b) were assessed 
quantitatively by analysing digital images for the number of polygonal spaces delimited by 
complete tubules (lumens). Results are expressed as means±sd. **, P<0.001 versus HCMV-derived 
secretome.  
 
 
 
 
 
 
 
Fig. 6. Recombinant IL-6 and GM-CSF promote lymphangiogenesis in cultured LECs. LECs 
were serum starved for 24 h in EBM plus 0.5% FBS and then treated for 24 h in the presence of 
EBM plus 0.5% FBS (a), supernatant from mock-infected LECs (b), EGM plus 2% FBS (c), mock-
infected LEC-derived secretome containing human recombinant MIP-3α (100 ng ml−1) (d), GM-
CSF (100 ng ml
−1
) (e) or IL-6 (100 ng ml
−1
) (f). After 24 h, the cells were harvested and transferred 
into BME-coated wells. The wells were then analysed for tube formation by examination with a 
phase-contrast inverted microscope at 8 h. Representative examples of each culture condition are 
shown. Magnification, ×10. Data are representative of three independent experiments with similar 
results.  
 
